Crossref


1. Pioglitazone for the Treatment of Metabolic-Associated Fatty Liver Disease in People Living With HIV and Prediabetes

- Sarunporn Kamolvisit

- Supphamat Chirnaksorn

- Hataikarn Nimitphong

- Somnuek Sungkanuparph

5. The association between liver function tests abnormalities and type 2 diabetes mellitus patients in Saudi Arabia: a cross-sectional study

- Nimer Mehyar

- Ziyad Alhajeri

- Muath Alosaimi

- Ziyad Alanazi

- Abdulkarim Alanazi

- Raghib Abusaris

6. Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)

- Giulio Marchesini

- Elisabetta Bugianesi

- Patrizia Burra

- Fabio Marra

- Luca Miele

- Anna Alisi

- Piero Vajro

- Mario Masarone

- Salvatore Petta

- Marcello Persico

- Gianluca Svegliati-Baroni

- Luca Valenti

- Massimo Federici

- Francesco Purrello

- Ferdinando Carlo Sasso

- Giovanni Targher

- Luca Busetto

- Maria Letizia Petroni

- Ferruccio Santini

- Calogero Cammà

- Agostino Colli

7. Prediction of Nonalcoholic Fatty Liver Disease Via a Novel Panel of Serum Adipokines

- Raika Jamali

- Abbas Arj

- Mohsen Razavizade

- Mohammad Hossein Aarabi

8. Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD)

- Rosa Lombardi

- Simona Onali

- Douglas Thorburn

- Brian R Davidson

- Kurinchi Selvan Gurusamy

- Emmanuel Tsochatzis

11. Serum adipokines might predict liver histology findings in non-alcoholic fatty liver disease

- Raika Jamali

- Mohsen Razavizade

- Abbas Arj

- Mohammad Hossein Aarabi

12. Cardiovascular protective effects of PPARγ agonists in hypothyroid rats: protection against oxidative stress

- Yousef Baghcheghi

- Farimah Beheshti

- Mahmoud Hosseini

- Arezoo Gowhari-Shabgah

- Mohammad Ali-Hassanzadeh

- Mahdiyeh Hedayati-Moghadam

13. The effect of pioglitazone on weight, lipid profile and liver enzymes in type 2 diabetic patients

- Nasser Aghamohammadzadeh

- Mitra Niafar

- Elham Dalir Abdolahinia

- Farzad Najafipour

- Saeed Mohamadzadeh Gharebaghi

- Khadijeh Adabi

- Elaheh Dalir Abdolahinia

- Hamidreza Ahadi

16. Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)

- Giulio Marchesini

- Elisabetta Bugianesi

- Patrizia Burra

- Fabio Marra

- Luca Miele

- Anna Alisi

- Piero Vajro

- Mario Masarone

- Salvatore Petta

- Marcello Persico

- Gianluca Svegliati-Baroni

- Luca Valenti

- Massimo Federici

- Francesco Purrello

- Ferdinando Carlo Sasso

- Giovanni Targher

- Luca Busetto

- Maria Letizia Petroni

- Ferruccio Santini

- Calogero Cammà

- Agostino Colli

17. Data on Adiponectin from 2010 to 2020: Therapeutic Target and Prognostic Factor for Liver Diseases?

- Misaq Heydari

- María Eugenia Cornide-Petronio

- Mónica B. Jiménez-Castro

- Carmen Peralta

19. The impact of metformin on weight and metabolic parameters in patients with obesity: A systematic review and meta‐analysis of randomized controlled trials

- Rachelle Haber

- Fatima Zarzour

- Malak Ghezzawi

- Natalie Saadeh

- Dania S. Bacha

- Lama Al Jebbawi

- Marlene Chakhtoura

- Christos S. Mantzoros

20. Levocetirizine ameliorates high fructose diet-induced insulin resistance, vascular dysfunction and hepatic steatosis in rats

- Noha M. Shawky

- George S.G. Shehatou

- Mona Abdel Rahim

- Ghada M. Suddek

- Nariman M. Gameil

25. The effects of pioglitazone and rosiglitazone on liver function in hypothyroid rats

- Yousef Baghcheghi

- Farimah Beheshti

- Fatemeh Seyedi

- Mahdiyeh Hedayati-Moghadam

- Hedyeh Askarpour

- Aliasghar Kheirkhah

- Ahmad Golkar

- Mohammad Dalfardi

- Mahmoud Hosseini

26. Effectiveness of drug interventions in nonalcoholic fatty liver disease: A network meta-analysis

- Yi-Zhou Huang

- Gang-Yi Yang

- Cong Wang

- Xing-Yu Chen

- Li-Li Zhang

28. The Effect of Berberis Vulgaris Extract on Transaminase Activities in Non-Alcoholic Fatty Liver Disease

- Raziye Iloon Kashkooli

- Seyed Saeed Najafi

- Farkhondeh Sharif

- Azadeh Hamedi

- Mohammad Kazem Hoseini Asl

- Majid Najafi Kalyani

- Mehdi Birjandi

30. The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review

- Maria Zachou

- Pagona Flevari

- Narjes Nasiri-Ansari

- Constantinos Varytimiadis

- Evangelos Kalaitzakis

- Eva Kassi

- Theodoros Androutsakos

36. Fatty Liver Index (FLI) in Predicting Non-alcoholic Fatty Liver Disease (NAFLD)

- Zahra Dehnavi

- Farkhonde Razmpour

- Mahmoud Belghaisi Naseri

- Mohsen Nematy

- Seyed Ali Alamdaran

- Hassan Ali Vatanparast

- Mohsen Azimi Nezhad

- Bita Abbasi

- Azita Ganji

38. Effect of canagliflozin on liver function tests in patients with type 2 diabetes

- L.A. Leiter

- T. Forst

- D. Polidori

- D.A. Balis

- J. Xie

- S. Sha

44. Antidiabetic drugs and non-alcoholic fatty liver disease: A systematic review, meta-analysis and evidence map

- Jai Kumar

- Roha Saeed Memon

- Izza Shahid

- Tehlil Rizwan

- Maryam Zaman

- Ritesh G. Menezes

- Sarwan Kumar

- Tariq Jamal Siddiqi

- Muhammad Shariq Usman